CoChat

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

Open access
Huang, Qian, Xia, Jiajia, Wang, Lei, Wang, Xu, Ma, Xiaodong, Deng, Qipan, Lu, Yong, Kumar, Munish, Zhou, Zhiyuan, Li, Ling, Zeng, Zhaoyang, Young, Ken H., Yi, Qing, Zhang, Mingzhi, Li, Yong · 2018 · Journal of Hematology & Oncology
Cited by 135

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first and rate-limiting step in converting tryptophan to kynurenine. Chimeric antigen receptor (CAR) T cells are T cells with recombinant receptors targeting tumor-associated antigens. The Food and Drug Administration has approved CAR T cells that target CD19 for treatment of advanced B cell leukemia and lymphoma. However, CAR T cell therapy in solid tumors has been hampered by multiple obstacles. Preclinical and clinical studies suggest that combinatorial immune checkpoint blockade and IDO1 inhibition provide durable therapeutic efficacy against cancer. Yet, the combination of IDO1 inhibition and CAR T has not been attempted. METHODS: We analyze IDO1 downregulation by miR-153 in colon cancer cells and the association of IDO1 and miR-153 expression with colorectal patient survival. We generate CAR T cells targeting the epidermal growth factor receptor variant III and measure their tumor killing effects against colon cancer cells with or without miR-153 overexpression by killing assays and in xenografts. RESULTS: IDO1 is highly expressed in colorectal tumors and is inversely associated with patient survival. miR-153 directly inhibits IDO1 expression by targeting its 3' untranslated region in colon cancer cells; yet, miR-153 overexpression does not affect cancer cell survival, apoptosis, and colony formation. When colon cancer cells are targeted by CAR T cells, miR-153 overexpression within tumor cells significantly enhances T cell killing in vitro and suppresses xenograft tumor growth in mice. CONCLUSIONS: These findings indicate that miR-153 inhibits IDO1 expression in colon cancer cells and is a tumor-suppressive miRNA that enhances CAR T cell immunotherapy. This study supports the combinatorial use of IDO1 inhibitors and CAR T cells in treating solid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-018-0600-x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 135

Metadata

Authors
Huang, Q., Xia, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., Zeng, Z., Young, K. H., Yi, Q., Zhang, M., & Li, Y.
Venue
Journal of Hematology & Oncology
Published
2018-04-23
Volume
11
Issue
1
Pages
58-58
ISSN
1756-8722 (ISSN-L)
OpenAlex
W2805860820
Cited by
135
References
9
FWCI
4.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. https://app.cochat.ai/papers/10.1186/s13045-018-0600-x
The paper
Huang, Q., Xia, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., Zeng, Z., Young, K. H., Yi, Q., Zhang, M., & Li, Y. (2018). miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-018-0600-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.